A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age19-70
SponsorNeuracle Science Co., LTD.
About this trial
The goal of this 2 step-up, exploratory study is to test safey, tolerability and PK/PD profiles in healthy volunteers and safety, tolerability and efficacy in sudden sensorineural hearing loss patients as an early salvage therapy.
The main questions it aims to answer are:
1. whether is it safe and tolerable when healthy volunteers and sudden sensorineural hearing loss patients take multiple doses of NS101 against FAM19A5 2. whether is it effective in reversing hearing capability in sudden sensorineural hearing loss patients who fails to show sufficient recovery despite of oral standard steroid therapy.
Patients and heathly volunteers will be given NS101 15mg/kg or 30mg/kg systemically less than 3 months per protocol.
This is placebo controlled, double blinded study, which means there will be a group who receives placebo (i.e. fake drug) for study purpose.
Eligibility criteria
Qualifiers
unilateral ideopathic SSNHL greater than 45dB at the average of 4 frequencies in PTA (contralateral hearing is less than 30dB)
Subject who has completed investigator-recognized standard treatment within 30 days of symptom onset and is able to undergo randomization visit within 35 days.
Subjects who, in the opinion of the investigator, have received sufficient systemic steroid therapy for approximately 2 weeks recovery
A combination regimen consisting of approximately 2 weeks of systemic steroid therapy and intratympanic steroid administration
Disqualifiers
other otologic or systemic diseases
retrocochlear lesion
Trial design
Treatments tested in this trial
- NS101
- Placebo
Treatment groups
138 Participants
are divided into 4 treatment groupsSponsors and collaborators
Neuracle Science Co., LTD.
Lead sponsor
Samsung Medical Center
Collaborator
Severance Hospital
Collaborator
Korea University Anam Hospital
Collaborator
Source ClinicalTrials.gov